ORIGINAL RESEARCH article

Front. Pharmacol.

Sec. Renal Pharmacology

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1565713

Bupropion decreases plasma levels of asymmetric dimethylarginine and ameliorates renal injury by modulation of Ddah1, Oatp4c1, Oct2, and Mate1 in rats with adenine-induced chronic renal injury

Provisionally accepted
Lulu  HuangLulu Huang1,2Yun  XiaoYun Xiao1,2Xiaoyu  HanXiaoyu Han1,2Yang  YuYang Yu2Chao  ZhengChao Zheng1,2Xiangdong  FangXiangdong Fang2Qing  LiQing Li2Fanglan  LiuFanglan Liu1Chunhua  XiaChunhua Xia1Yongjie  ZhangYongjie Zhang3Jiake  HeJiake He2*
  • 1School of Pharmacy, Nanchang University, Nanchang, Jiangxi Province, China
  • 2Second Affiliated Hospital of Nanchang University, Nanchang, China
  • 3China Pharmaceutical University, Nanjing, Jiangsu Province, China

The final, formatted version of the article will be published soon.

Objective: The objective of the study was to investigate whether bupropion (BUP) or its circulation metabolites could decrease plasma level of asymmetric dimethylarginine (ADMA) and ameliorate renal injury by modulation of Ddah1, Oatp4c1, Oct2, and Mate1 in rats with adenine-induced chronic renal injury. Methods: The study initially determined the effect of BUP and its metabolites on cell viability and apoptosis in HK2 cells in the presence and absence of ADMA. Secondly, the study explored whether long-term administration of BUP could reduce the plasma level of ADMA and mitigate renal damage. Thirdly, the expression and activity of Oct2, Ddah1, Mate1 and Oatp4c1 was determined by western blot and UPLC-MS/MS.Results: With 0.5 μmol/L ADMA, hydroxybupropion (HBUP, 100 nmol/L), threo-hydrobupropion (TBUP, 10 nmol/L and 1 μmol/L) reduced N-Acetyl-β-D-glucosidase (NAG) level. At 5 μmol/L ADMA, BUP (1 nmol/L-1 μmol/L), HBUP (1-100 nmol/L), and BUP cocktail enhanced survival. At 50 μmol/L ADMA, HBUP (10 nmol/L and 1 μmol/L), TBUP/erythro-hydrobupropion (EBUP) (10-100 nmol/L), and BUP cocktail stimulated survival. EBUP (1/100 nmol/L) lowered LDH. BUP (100 nmol/L) and TBUP (1 μmol/L) decreased NAG. TBUP (10 nmol/L/1 μmol/L) and EBUP (100 nmol/L) inhibited apoptosis. In adenine-induced chronic renal injury rats, long-term administration of BUP significantly decreased the serum concentration of ADMA and creatinine by 12.78 % and 38.85 %, respectively, ameliorated interstitial lesions and fibrosis and upregulated Ddah1, Oatp4c1, Oct2, Mate1. BUP increased metformin renal clearance without affecting digoxin disposition.Conclusion: Bupropion moderately decreases plasma levels of ADMA and ameliorates renal injury by modulation of Ddah1, Oatp4c1, Oct2, and Mate1.

Keywords: bupropion and its metabolites, Asymmetrical dimethylarginine, Chronic kidney injury, Renal transporters, Metabolism enzyme

Received: 23 Jan 2025; Accepted: 02 May 2025.

Copyright: © 2025 Huang, Xiao, Han, Yu, Zheng, Fang, Li, Liu, Xia, Zhang and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Jiake He, Second Affiliated Hospital of Nanchang University, Nanchang, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.